A phase 2, open-label trial to evaluate the efficacy and safety of MGCD0103 [MGCD 0103] administered in combination with azacitidine (Vidaza) to subjects with relapsed or refractory Hodgkin's or non-Hodgkin's lymphoma, and to evaluate the pharmacokinetics of MGCD0103 and FB-MGCD0103

Trial Profile

A phase 2, open-label trial to evaluate the efficacy and safety of MGCD0103 [MGCD 0103] administered in combination with azacitidine (Vidaza) to subjects with relapsed or refractory Hodgkin's or non-Hodgkin's lymphoma, and to evaluate the pharmacokinetics of MGCD0103 and FB-MGCD0103

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2015

At a glance

  • Drugs Azacitidine; Azacitidine; Mocetinostat
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Celgene Corporation; Mirati Therapeutics; Pharmion Corporation
  • Most Recent Events

    • 08 Dec 2008 Status changed from suspended to discontinued, based on information from ClinicalTrials.gov. This trial has been closed as Celgene has terminated its collaborative agreement, with MethylGene, for the development of MGCD0103.
    • 22 Sep 2008 Celgene Corporation reported as a company Affiliate and Sponsor by ClinicalTrials.gov.
    • 23 Jul 2008 Status changed from recruiting to in progress, as reported on clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top